$1.68
-0.04 (-2.33%)
Open$1.74
Previous Close$1.72
Day High$1.80
Day Low$1.65
52W High$9.59
52W Low$1.51
Volume—
Avg Volume107.2K
Market Cap5.99M
P/E Ratio—
EPS$-1.53
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+378.6% upside
Current
$1.68
$1.68
Target
$8.04
$8.04
$5.03
$8.04 avg
$9.33
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.65M | 5.72M | 5.36M |
| Net Income | 307.3K | 283.7K | 353.7K |
| Profit Margin | 5.4% | 5.0% | 6.6% |
| EBITDA | 445.8K | 473.3K | 433.9K |
| Free Cash Flow | 346.8K | 407.6K | 312.1K |
| Rev Growth | +24.0% | +14.6% | +14.6% |
| Debt/Equity | 0.71 | 0.92 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |